Re:23andMe has signed a $300M deal with GlaxoSmithKline
by Real_S on Saturday January 05, 2019 @11:09AM
(#18832336)
There is no reason to think that they are not sequencing some of these samples in their research programs, and/or waiting for sequencing to become cheap enough to do so. Considering that there are numerous large GWAS studies around, why would pharma pay big money for access to this data if it were limited to GWAS? They might currently only sequence specific genes and/or specific individuals, guided by the GWAS data, but as sequencing gets cheaper there is nothing stopping them from full genome sequencing in their research.
Their prices are low for the "consumer" (product). The $300 million GSK deal is an example of how they can make real money.
Re:23andMe has signed a $300M deal with GlaxoSmithKline
by steve_musk on Saturday January 05, 2019 @12:11PM
(#18832763)
When you sign up they ask you if they can store your DNA sample for up to 10 years. I assume this is so they can sequence it once it becomes cheaper.
I think your point still stands though, your genotype is still identifying information and should be safeguarded.
https://customercare.23andme.com/hc/en-us/articles/202904600...